{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:50:45Z","timestamp":1781923845809,"version":"3.54.5"},"reference-count":36,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis aims to compare BT and DT in terms of intraocular pressure (IOP) reduction, safety, and patient preferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following PRISMA and Cochrane guidelines, we searched PubMed, Scopus, Web of Science, CENTRAL, and Embase up to December 30, 2024. Twelve studies (11 randomized controlled trials [RCTs]) involving 1,885 patients were included. Primary outcomes were IOP reduction and adverse events. Statistical analyses were performed using Review Manager 5.4.1, with mean differences (MD) and risk ratios (RR) calculated for continuous and binary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      BT demonstrated a statistically greater reduction in the morning IOP compared to DT at 12 weeks or more (BT: MD\u2009=\u20090.56 mmHg,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001; BTFC subgroup: MD\u2009=\u20090.66,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001), with consistent benefits observed at 8 and 4 weeks. No significant difference was observed in the evening IOP reduction. BT combination was associated with a 49% lower risk of eye irritation (RR\u2009=\u20090.51,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001) but a threefold higher risk of blurred vision (RR\u2009=\u20093.14,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patient preference studies favored brinzolamide\/timolol fixed combination (BTFC) due to reduced ocular discomfort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BT showed a statistically greater reduction in morning IOP than DT; however, the absolute difference was modest, and its clinical relevance is uncertain. BT was associated with less ocular irritation but higher blurred vision risk. High heterogeneity for evening IOP and overall adverse events limits interpretation. Considering these findings, the choice of treatment usually depends on the patient's tolerance to higher initial ocular irritation in DT or blurring of vision in BT. Longer-term trials with 24-h IOP and preference are needed to assess these outcomes meaningfully.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11206721261422832","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:27:17Z","timestamp":1771262837000},"page":"790-804","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative safety and efficacy of brinzolamide\/timolol and dorzolamide\/timolol in the treatment of glaucoma patients: A systematic review and meta-analysis"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1520-5311","authenticated-orcid":false,"given":"Anas","family":"Alamoudi","sequence":"first","affiliation":[{"name":"Jeddah Eye Hospital"},{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5968-2662","authenticated-orcid":false,"given":"Ahmed","family":"Alnabihi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"Department of Ophthalmology, King Khaled Eye Specialist Hospital and Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2301-2218","authenticated-orcid":false,"given":"Sultan","family":"Al-Qahtani","sequence":"additional","affiliation":[{"name":"University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-8805","authenticated-orcid":false,"given":"Asim M","family":"Albishry","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"Department of Ophthalmology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4596-735X","authenticated-orcid":false,"given":"Waleed K","family":"Alsarhani","sequence":"additional","affiliation":[{"name":"University of Toronto"},{"name":"Department of Ophthalmology, King Faisal Specialist Hospital &amp; Research Centre, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-9154","authenticated-orcid":false,"given":"Hady","family":"Saheb","sequence":"additional","affiliation":[{"name":"McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5600-7242","authenticated-orcid":false,"given":"Iqbal Ike K","family":"Ahmed","sequence":"additional","affiliation":[{"name":"University of Toronto"},{"name":"John A. Moran Eye Center, University of Utah, Salt Lake City, USA"},{"name":"Prism Eye Institute, Mississauga, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfop.2024.100142"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2011.1936"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192"},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","unstructured":"European glaucoma society terminology and guidelines for glaucoma 5th edition. Br J Ophthalmol 2021 Jun;105:1\u2013169.","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01525-5"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00679"},{"key":"e_1_3_3_8_2","doi-asserted-by":"crossref","unstructured":"Michelessi M Lindsley K Yu T et al. Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysis. Cochrane Eyes and Vision Group editor. Cochrane Database Syst Rev [Internet]. 2018 May 30 [cited 2024 Dec 30]; Available from: https:\/\/doi.wiley.com\/10.1002\/14651858.CD011366.pub2.","DOI":"10.1002\/14651858.CD011366.pub2"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.179718"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1578_21"},{"key":"e_1_3_3_11_2","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2024 Apr 5]. Available from: https:\/\/training.cochrane.org\/handbook"},{"key":"e_1_3_3_12_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J 2021 Mar 29; 372: n71.","journal-title":"Br Med J"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_3_14_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"4898","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J 2019 Aug 28; l4898.","journal-title":"Br Med J"},{"key":"e_1_3_3_15_2","unstructured":"GRADE Working Group. GRADE Handbook for grading quality of evidence and strength of recommendations [Internet]. The GRADE Working Group; 2013. Available from: https:\/\/book.gradepro.org\/."},{"key":"e_1_3_3_16_2","doi-asserted-by":"crossref","unstructured":"Aihara M Adachi M Matsuo H et al. Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Acta Ophthalmol (Copenh) [Internet]. 2017 Dec [cited 2024 Dec 30];95(8). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.13401.","DOI":"10.1111\/aos.13401"},{"key":"e_1_3_3_17_2","article-title":"Brinzolamide 1%\/timolol versus dorzolamide 2%\/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study","volume":"2263","author":"Altafini R","year":"2015","unstructured":"Altafini R, Scherzer ML, Hubatsch D, et al. Brinzolamide 1%\/timolol versus dorzolamide 2%\/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study. Clin Ophthalmol 2015 Dec; 2263.","journal-title":"Clin Ophthalmol"},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","unstructured":"Bhagat P Singhania M Navare S et al. Efficacy and Safety of a Fixed-Dose Combination of Brinzolamide 1%\/Timolol 0.5% vs. Dorzolamide 2%\/Timolol 0.5% in Indian Patients With Primary Open-Angle Glaucoma or Ocular Hypertension: A Randomized Phase 3 Study. Cureus [Internet]. 2024 Nov 13 [cited 2024 Dec 30]; Available from: https:\/\/www.cureus.com\/articles\/269085-efficacy-and-safety-of-a-fixed-dose-combination-of-brinzolamide-1timolol-05-vs-dorzolamide-2timolol-05-in-indian-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension-a-randomized-phase-3-study.","DOI":"10.7759\/cureus.73599"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2012.754479"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31818fb434"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2008.0114"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)00974-6"},{"key":"e_1_3_3_23_2","article-title":"A patient preference comparison of Azarga&trade; (brinzolamide\/timolol fixed combination) vs Cosopt&reg; (dorzolamide\/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension","volume":"623","author":"Mundorf T","year":"2008","unstructured":"Mundorf T, Rauchman S, Williams R, et al. A patient preference comparison of Azarga&trade; (brinzolamide\/timolol fixed combination) vs Cosopt&reg; (dorzolamide\/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008 Oct;623.","journal-title":"Clin Ophthalmol"},{"key":"e_1_3_3_24_2","article-title":"Preference for a fixed combination of brinzolamide\/timolol versus dorzolamide\/ timolol among patients with open-angle glaucoma or ocular hypertension","volume":"357","author":"Sanseau A","year":"2013","unstructured":"Sanseau A Lopes, Borel, et al. Preference for a fixed combination of brinzolamide\/timolol versus dorzolamide\/ timolol among patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2013 Feb; 357.","journal-title":"Clin Ophthalmol"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.1.48"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2012.05.003"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.22336\/rjo.2019.32"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.192922"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307674"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2019.09.004"},{"key":"e_1_3_3_31_2","article-title":"Efficiency, safety, and patient preference of switching from dorzolamide 1%\/timolol 0.5% to brinzolamide 1%\/timolol 0.5% while maintaining the prostaglandin F2&alpha; analog","volume":"475","author":"Shimizu Y","year":"2015","unstructured":"Shimizu Y, Nakakura S, Nishiyama M, et al. Efficiency, safety, and patient preference of switching from dorzolamide 1%\/timolol 0.5% to brinzolamide 1%\/timolol 0.5% while maintaining the prostaglandin F2&alpha; analog. Clin Ophthalmol 2015 Mar; 475.","journal-title":"Clin Ophthalmol"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0875-7"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200208000-00013"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3015(11)73367-8"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874364101408010067"},{"key":"e_1_3_3_36_2","doi-asserted-by":"crossref","unstructured":"Lazreg S Assaf AH Abdelrahman AM et al. Efficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide\/timolol) in ocular hypertension and\/or glaucoma. Int Ophthalmol [Internet]. 2025 Jan 20 [cited 2025 Jul 23];45(1). Available from: https:\/\/link.springer.com\/10.1007\/s10792-025-03411-x.","DOI":"10.1007\/s10792-025-03411-x"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1397-7"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721261422832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721261422832","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721261422832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:02:16Z","timestamp":1781920936000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721261422832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/11206721261422832"],"URL":"https:\/\/doi.org\/10.1177\/11206721261422832","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}